Largactil Iv

Chlorpromazine, the active ingredient in Largactil Iv, is a phenothiazine antipsychotic presented as an injectable solution for intravenous use. It treats schizophrenia, acute psychosis, manic episodes, severe nausea and vomiting, and provides preoperative sedation in appropriate patients.

GNH USA supplies Largactil Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Chlorpromazine is a phenothiazine antipsychotic that modulates dopaminergic and other neurotransmitter pathways.

- Schizophrenia: reduces delusions, hallucinations and other psychotic symptoms. - Acute psychosis: stabilises severe agitation and psychotic disturbances. - Manic episodes: helps control elevated mood and hyperactivity. - Severe nausea and vomiting: provides antiemetic relief when other agents are insufficient. - Preoperative sedation: produces calming and anxiolytic effects before surgery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Sedation: drowsiness or reduced alertness. - Orthostatic hypotension: dizziness upon standing. - Anticholinergic effects: dry mouth, blurred vision, constipation. - Weight gain: increased appetite and body weight.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Cardiac arrhythmias: QT prolongation leading to torsades de pointes. - Tardive dyskinesia: persistent involuntary movements of the face or limbs.

Before initiating therapy, clinicians should consider several safety factors.

- Blood pressure monitoring: watch for orthostatic hypotension, especially after the first dose. - Cardiac assessment: evaluate QT interval and history of arrhythmias. - Hepatic function: adjust use in patients with significant liver impairment. - Elderly patients: use cautiously due to increased risk of sedation and falls. - Hypersensitivity: discontinue if allergic reactions such as rash or bronchospasm occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Chlorpromazine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CNS depressants: enhanced sedation and respiratory depression. - Antihypertensives: additive hypotensive effects. - QT‑prolonging agents: increased risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): may raise chlorpromazine plasma levels. - Lithium: concurrent use can increase lithium toxicity.